Fruit fly study identifies potential therapeutic target for form of ALS, FTD
UF neuroscientists collaborate on international study revealing a potential therapeutic target for ALS, FTD linked to TDP-43.
Posted in
ALS, MS And NM Clinic
Celine Dion’s diagnosis of stiff-person syndrome brought a rare neurological diagnosis into the public eye – two neurologists explain the science behind it
In The Conversation, Drs. Bhavana Patel and Torge Rempe explain stiff person syndrome, its symptoms, treatment approaches and more.
The connection between MOGAD and seizures
Dr. Mayra Montalvo provides an insight on the clinical picture and outcomes of patients with seizures and myelin oligodendrocyte glycoprotein antibody disease.
FDA approves new ALS drug tested in clinical trial at UF
AMX0035 was tested at UF, Mass General and partnering sites and then approved by the FDA to treat ALS.
Alert, but mute and motionless: a case of acute akinetic mutism
Researchers explore a case of acute akinetic mutism caused by cerebral fat embolisms from hemoglobin sickle cell disease.
Identifying the specific brain network to suppress MS tremor via DBS
UF neurologists identify a distinct collection of brain fibers to target with deep brain stimulation for tremor suppression in multiple sclerosis.
Researchers report experimental drug may prolong survival in ALS patients
Trial drug combination shows potential to prolong survival of ALS patients by more than six months.
Researchers report experimental drug may prolong survival in ALS patients
Trial drug combination shows potential to prolong survival of ALS patients by more than six months.
UF researchers help lead international studies into two rare neuromuscular disorders
UF researchers team up with international partners to improve understanding and treatment of two rare hereditary neuromuscular disorders.
New trial drug combination shows promise for slowing progression of ALS
UF was the No. 2 enroller of patients for multisite ALS trial.
